Skip to content
OpenCapital
Get started

Tarsus Pharmaceuticals, Inc. TARS Performance stock units issued and outstanding (unvested) under the 2020 Plan (in shares)

Other financials

Income statement

See full
Revenue$162.1M+107%
Gross profit$152.7M+109%
Operating income-$6.1M+76.7%
Net income-$7.0M+72.3%
EPS (diluted)-$0.16+75.0%

Balance sheet

See full
Cash & equivalents$104.2M-41.6%
Total debt$88.7M+22.5%
Total equity$349.0M+1.9%
Total assets$581.1M+16.1%

Cash flow

See full
Operating cash flow-$24.7M-19.4%
CapEx$5.8M+886%
Free cash flow-$30.5M-43.4%

Valuation

See full
Market cap$2.85B+41.1%
Enterprise value$2.83B+47.8%
P/S5.3×-3.3×

Profitability

See full
Gross margin42.7%—
Operating margin-9.5%-4.2pp
Net margin-9%-4.0pp
FCF margin-28%-12.6pp

Returns & leverage

See full
Return on equity-14%-5.2pp
Debt / equity0.3×0.0×
Current ratio3.7×-1.8×

Where this comes from

Reported directly by Tarsus Pharmaceuticals, Inc. in its filing.

Tagged under the XBRL concept tars:CommonStockCapitalSharesReservedForFutureIssuanceEffectOfPerformanceStockUnitsAvailableForFutureGrant.

The official record: Tarsus Pharmaceuticals, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Tarsus Pharmaceuticals, Inc.'s performance stock units issued and outstanding (unvested) under the 2020 plan (in shares).

Connect your AI assistant and see it in context, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Tarsus Pharmaceuticals, Inc.'s performance stock units issued and outstanding (unvested) under the 2020 plan (in shares)?
Tarsus Pharmaceuticals, Inc. (TARS) reported performance stock units issued and outstanding (unvested) under the 2020 plan (in shares) of 721.3K in Q1 2026.
How has Tarsus Pharmaceuticals, Inc.'s performance stock units issued and outstanding (unvested) under the 2020 plan (in shares) changed year-over-year?
Tarsus Pharmaceuticals, Inc.'s performance stock units issued and outstanding (unvested) under the 2020 plan (in shares) increased by 4.1% year-over-year, from 692.6K to 721.3K.